UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000029511
Receipt No. R000033721
Scientific Title Dose determination study of Nanoparticulated Brown Rice Germ Extract on Body Fat Reduction by Daily Ingestion.
Date of disclosure of the study information 2017/10/13
Last modified on 2018/07/20

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Dose determination study of Nanoparticulated Brown Rice Germ Extract on Body Fat Reduction by Daily Ingestion.
Acronym Effects of Reducing Body Fat by Daily Ingestion of Nanoparticulated Brown Rice Germ Extract.
Scientific Title Dose determination study of Nanoparticulated Brown Rice Germ Extract on Body Fat Reduction by Daily Ingestion.
Scientific Title:Acronym Effects of Reducing Body Fat by Daily Ingestion of Nanoparticulated Brown Rice Germ Extract.
Region
Japan

Condition
Condition Healthy adults
Classification by specialty
Not applicable Adult
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To prove clinical benefits associated with daily nanoparticulated brown rice germ extract ingestion for 12 weeks on body fat reduction by which the potential health benefits of the brown rice extract is investigated.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2 Pragmatic
Developmental phase Not applicable

Assessment
Primary outcomes Abdominal visceral fat area after 4, 8 and 12 weeks of ingestion.
Key secondary outcomes body weight, BFP, BMI, waist circumference, TC, LDL-C, HDL-C, TG, LDL-C/HDL-C, non-HDL, fasting blood glucose levels, HbA1c, insulin, HOMA-IR, adiponectin , leptin, Olfactory test and DASC-21.

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Double blind -all involved are blinded
Control Placebo
Stratification YES
Dynamic allocation NO
Institution consideration Institution is not considered as adjustment factor.
Blocking YES
Concealment No need to know

Intervention
No. of arms 6
Purpose of intervention Treatment
Type of intervention
Food
Interventions/Control_1 Ingestion of 2 tablets of nanoparticulated brown rice germ extract (high dose) daily for 12 weeks.
Interventions/Control_2 Ingestion of 2 tablets of nanoparticulated brown rice germ extract (medium dose) daily for 12 weeks.
Interventions/Control_3 Ingestion of 2 tablets of nanoparticulated brown rice germ extract (low dose) daily for 12 weeks.
Interventions/Control_4 Ingestion of 2 tablets of placebo tablet daily for 12 weeks.
Interventions/Control_5 Ingestion of 15g of rice bran oil containing nanoparticulated rice germ extract daily for 12 weeks.
Interventions/Control_6 Ingestion of 15g of placebo oil (normal rice bran oil) daily for 12 weeks.
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
65 years-old >
Gender Male and Female
Key inclusion criteria 1.Subjects whose BMI is >=23 kg/m2 and <30 kg/m2.
2.Subjects whose Abdominal visceral fat area is <100cm2.
3.Subjects who agree to participate in this study with a written informed consent.
Key exclusion criteria 1.Subjects who are under physician's advice, treatment and/or medication for obese, hyperlipidemia and diabetes.
2.Subjects with familial hypercholesterolemia.
3.Subjects with serious cerebrovascular, cardiac, hepatic, renal, gastrointestinal diseases, and/or affected with infectious diseases requiring reports to the authorities.
4.Pacemaker or defibrillator users.
5.Subjects with major surgical history relevant to digestive system such as gastrectomy, gastrorrhaphy, enterectomy, etc.
6.Subjects with unusually high and/or low blood pressure and/or abnormal hematological data.
7.Subjects with severe anemia.
8.Pre- or post-menopausal women complaining obvious physical changes.
9.Subjects who are at risk of having allergic reactions to drugs or foods, especially gramineae.
10.Subjects who regularly take medicine, functional foods, and/or supplements which would affect BW and BFP.
11.Subjects who regularly take medicine, functional foods, and/or supplements which would affect blood lipid levels.
12.Subjects who regularly take medicine, functional foods and/or supplements which would affect glucose metabolism.
13.Heavy smokers, alcohol addicts or subjects with the eating disordered lifestyle.
14.Subjects who donated either 400ml whole blood within 16 weeks (women) /12 weeks (men) or 200ml whole blood within 4 weeks or blood components within 2 weeks prior to the current study.
15.Pregnant or lactating women or women expect to be pregnant during this study.
16.Subjects who currently participate in other clinical trials or participated within the last 4 weeks prior to the current study.
17.Any other medical and/ or health reasons unfavorable to participation into the current study judged by the principal investigator.
Target sample size 120

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Prof. Jun NISHIHIRA, M.D., Ph.D.
Organization Hokkaido Information University
Division name Department of Medical Management and Informatics
Zip code
Address 59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan
TEL 011-385-4411
Email nishihira@do-johodai.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Dir. Prof. Jun NISHIHIRA, M.D., Ph.D.
Organization Hokkaido Information University
Division name Health Information Science Center
Zip code
Address 59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan
TEL 011-385-4430
Homepage URL
Email nishihira@do-johodai.ac.jp

Sponsor
Institute Hokkaido Information University
Institute
Department

Funding Source
Organization SENTAN Pharma Inc.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization Japan

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 北海道情報大学 保健センター(北海道)

Other administrative information
Date of disclosure of the study information
2017 Year 10 Month 13 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2017 Year 09 Month 25 Day
Date of IRB
Anticipated trial start date
2017 Year 10 Month 18 Day
Last follow-up date
2018 Year 02 Month 12 Day
Date of closure to data entry
2018 Year 02 Month 25 Day
Date trial data considered complete
2018 Year 02 Month 26 Day
Date analysis concluded
2018 Year 05 Month 14 Day

Other
Other related information

Management information
Registered date
2017 Year 10 Month 11 Day
Last modified on
2018 Year 07 Month 20 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033721

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.